Innovating in ready-to-market formulations
17 Jan 2019 | Lonza (Capsugel)
Stephane Vouche, of Lonza Capsugel, spoke to NutritionInsight at Health Ingredients Europe (HiE) in 2018 on innovating in ready-to-market formulations. Vouche shared that Lonza was presenting new formulations at the show. One particular innovation included a combination capsule with Lonza's UCT-II ingredient for joint health with curcumin. This combination creates a powerful one-pill solution, meaning consumers do not need to take multiple pills, Vouche said.
This is Lisa Gunn at HIE 2018 in Frankfurt, and I'm here at the Lanza stand joined by Stefan.
Now this year at HIE Lanza is showcasing quite a lot of ready to market products.
What has informed this shift?
I think we have kind of, we have been developing a lot of new products that are.
Supporting really an easy way for our customers to go to market much faster than in the past with what we call ready to market solutions, and we are very proud here at the show to introduce a series of new formulations, ready to market products in that sense.
And just to start with, our very first product is using in fact our UC2 UC 2 formulation, which is in fact And a unique ingredient for joint health, unique because it's a mode of action, unique because of the small dosage that that is required for the consumer to really be a real help for everything that is related related to joint health problems.
We are presenting it here in in the VCPs capsule with a formulation where they are.
EFSA claims are guaranteed with additional ingredients, but it doesn't stop there, of course.
There are also other new formulations presented here which are using again the UC2 product, but here in a small capsule into our duoup formulation and where we are combining it with curcumin.
And this is where you really come to a very powerful solution in that sense that where the UC2 ingredients is known to be very effective in the small dosage form to compared to alternative solutions where you need to take multiple tablets.
And when you know that the curcumin is a high bioavailability format where again you need to take multiple alternative dosage forms to reach any effect, here you just have to take one small duo cap capsule, which is, I would call real innovation.
Now when it comes to appealing to consumers, it's often heard that there's a lot of pill fatigue.
When it comes to actually appealing to consumers, what are some of the newer technologies or, or, or maybe the products that you brought today?
There's there's a very nice classic example, I would say it's the multivitamin K.
So many many multivitamins still come in plastic tablets or powder formulations.
What we are presenting here is for these customers that really want to appeal to new categories or segments of users, consumers in the market.
We are presenting here.
The vitamin under a beetlet format, so you will find in this formulation a series of vitamins coated onto the beatlets and have an additional series of vitamins in the liquid format.
It's just like you would vitaminize your vitamins.
Now more forward looking, maybe, what are some of the areas we can expect further R&D in or further investment or or further interest?
Next to the fact that we already start to continue on the theme of bioavailability by putting Boswellia, which is a very traditional reagent I'm showing you, into the ayurvedic medicine, using a high bioavailability formulation, the theme like mobility.
Would certainly be a driver in any future to markets that will come, and I would really challenge the The visitor on our boat to discuss with us about what these challenges are to review what is driving mobility into the consumer health nutrition space, because it can be the active younger user.
It can be people facing.
Issues that are related to age, but it can also be related to issues related to vision as an example.
Thank you very much.
Thank you.
